What’s up everyone so in today’s video, I share with you two strong penny stocks,
which have strong product pipelines and news which could drive explosive growth over the
short term.. One of these hot penny stocks has analysts saying Buy and Billionaire Investor,
Steve Cohen piling onto it, based on their solid outlook potential. So make sure you
watch till the end so you don’t miss out on these big swing trade opportunities which
could make you good returns in the very short term. You also need to be aware that penny
stock investing is risky and so only get in if the price is right for you and don’t
invest any money you can’t afford to lose, as this is not financial advise... So make
sure you don’t miss out on these big bangers by liking the video and turn on the notification
bell to get these hot penny stocks instantly. So if you do end up enjoying this content,
please make sure to subscribe as its free and you can always change your mind.. And
also if you want two free stocks worth over $1800 from Webull and also where you can buy
fractional shares, please hit the link in the top comment or description below. I would
really appreciate it. Thank you so much.
So let’s get straight into it, with our number 2 penny stock here, which is Healthy
Extracts (HYEX); it has a share price sitting at 9cents and market cap of $28.6m. This penny
stock is up 50% over the last 5 days and also up 12.5% over the last 6 months. As you can
see this penny stock is very sensitive and hence volatile, which means it could be a
good swing trade opportunity, should you get in at the right price. Its trading at its
highs of 9 cents right now on the back of recent news, so my strike price would be within
the 5 to 6 cents range. So you need to wait this one out for it to pull right back so
you get the chance to double you money on the back of the next news update. Healthy
Extracts is OTC QB Listed with an average of 10.4k shares traded over a 30day period
and over 318mn shares outstanding.
Healthy Extracts Inc. (HYEX), through its growing portfolio of wholly owned subsidiaries,
is engaged in the proprietary research and development of natural plant-based formulations,
sales, and distribution of cardiovascular and neuro products. The company’s focus
is to advance its market positions in the broader health industry through the unique
assets and operations of its science-based BergaMet North America and Ultimate Brain
Nutrients (“UBN”) subsidiaries and to offer better lifestyles through superior health
technology.
In their latest results updates, they reported revenue increases of 71% to $1,276,559 for
the 12 months to December 2020, compared to revenues of $748,377 reported for 2019. The
Company attributes the increases to the transition to its new business selling health nutrition
products, seeing favorable results despite the effects of COVID. The Company also eliminated
its convertible debt.
Healthy Extracts very recently introduced a Breakthrough Nutraceutical Formulation,
Ultimate Brain Nutrients ACTIVATE™, which is Clinically Proven to Enhance Key Brain
Activity by 46%
Clinical studies have shown that ACTIVATE dramatically improves human cognitive behavior
and mental focus by activating areas of the brain primarily responsible for attention,
memory, mood, and quick reaction times.
ACTIVATE addresses the rapidly expanding brain health supplements market, which is expected
to grow at an 8.0% compounded annual growth rate (CAGR) to reach $13.4 billion by 2028.
It also targets the faster growing niche market for nootropics, substances designed to improve
memory, creativity and motivation. The nootropics market totaled $2.4 billion in 2020, and is
projected to reach $6.3 billion by 2028, growing at a CAGR of 12.7%.
Next up to our number 1 penny stock, which is Aerpio Pharmaceuticals Inc (ARPO). It has
a share price of $2.50 and market cap of $118.4m. Its share price is up 46% over the last 5
days on the back of recent news and over the last 6 months this stock is up by 111.8%.
This stock popped recently making it trade at 52 week highs and we can see from its track
record that it tends to pop and then pull back. So as we always buy low and sell high
we need to give room for this to pull back from this highs. So my strike price on this
one will be between $1.75 and $2.25. So if there’s any further pull back towards $2.25
that would be a good entry point.. This penny stock is Nasdaq listed with an average of
over 9.8m shares traded, over a 30day period and 47.3m shares outstanding.
Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class
treatments for vascular pathologies, a key regulator of blood vessel integrity. They
believe their Tie2 activation may reduce covid 19 related pulmonary complications including
the need for mechanical ventilation. I believe this would be game changing and take covid
critical cases treatment to another level. Tie2 is considered a key regulator of vascular
stability, and ARPO “believes that activation of Tie2 may have therapeutic potential”
for different indications.
In their Q1, 21 update, they ended up with $39.0 million in cash and equivalents.
They entered into an agreement and plan of merger with Aadi Bioscience, Inc., and Aspen
Merger Subsidiary. Following the proposed merger, Aerpio will change its name to “Aadi
Bioscience Inc.” and the combined public company will focus on advancing Aadi’s lead
product candidate, FYARROTM.
Aadi Bioscience is a privately-held biopharmaceutical company focusing on precision therapies for
genetically-defined cancers with alterations in mTOR pathway genes. The transaction will
create a Nasdaq-listed company focused on advancing Aadi Bioscience’s late-stage pipeline
for genetically-defined cancers with alterations in mTOR pathway genes. The Concurrent $155
million PIPE financing at closing is expected to fund operations into 2024. And the rolling
NDA submission to the FDA for FYARROTM is expected to be completed in mid-2021
An Analyst Robert Burns from H.C. Wainwright upgraded the stock to a Buy from a Hold and
set a post-merger price target of $22 per share.
The analyst noted that the company plans to effect a reverse stock split of around 317.2
million outstanding shares (by his estimate) after completion of the merger. The analyst
added, “While the nature of the reverse split has not been disclosed, for the purposes
of forecasting they have assumed a 7:1 ratio, which implies a post-reverse split/post-merger
closing share count of approximately 45M.”
He also has two reasons for being optimistic about FYARRO. First, the drug uses sirolimus
“as an active moiety.”, which is known to have crucial functions in mediating cancer
cell division as well as the ability of cancer cells to evade the immune system,” that
could benefit FYARRO. Secondly, he notes that FYARRO uses “the
same albuminbound nanoparticle delivery technology inherent in Abraxane (nab-paclitaxel), which
was originally approved in 2005 by the FDA for treatment of metastatic breast cancer
(mBC) and subsequently received U.S. regulatory approval in treatment of a range of other
cancers, notably lung cancer (NSCLC) and pancreatic cancer.”
The analyst noted that considering the success of Abraxane, which generated sales of $1.25
billion in FY20, he expects FYARRO to generate sales exceeding $2 billion by 2035.
Burns is the only analyst to have provided a rating on the stock in the last three months.
His price target of $22 implies approximately 780% upside potential to current levels over
the next 12 months, which is very bullish but yet exciting.
The top shareholders in Aerpio own over 62% of the shares which is a combination of hedge
funds and investment advisors. The top shareholder being Satter Management with 5.6m shares worth
11.8% weighting. We can also see Steve’s Cohen Point 72 Asset Management making a new
entry into this stock recently in May with 1.8m shares worth 3.84% which is significant.
So a very interesting and mind-blowing prospects ahead for these penny stocks.
This video is not financial advice, a buy or a sell recommendation, but is meant to
bring some new and exciting stocks to your attention for you to do your own research..
As always I would love to hear from you, so please let me know your thoughts on these
penny stocks in the comments section below and what other penny stocks are catching your
eyes lately. And If you are new to my channel please ensure
to subscribe and hit the bell so you are notified when I upload new videos. If you would like
to see more videos like this, please check out this video right here or this playlist
right here to watch equally insightful content from the channel. Thank you so much for being
here and I look forward to have you in my next video. Thank you